Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays

Thrombosis Research

Volumn 115, Issue 6, 2005, Pages 509-517

  Liestøl, Sigurd ^a   Wisløff, Finn ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Heparin neutralization; Low molecular weight heparin; Lupus anticoagulant assays; Normalized screening confirm ratio

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DVV CONFIRM; DVV TEST; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; REAGENT; STACLOT;

ADULT; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MALE; PRIORITY JOURNAL; SCREENING TEST; STATISTICAL ANALYSIS;

EID: 15744403969     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.11.013     Document Type: Article

References (17)

1. P.M. Mannucci, M.T. Canciani, D. Mari, and P. Meucci The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant Scand. J. Haematol. 22 5 1979 423 432
2. J.T. Brandt, and D.A. Triplett The effect of phospholipid on the detection of lupus anticoagulants by the dilute Russell viper venom time Arch. Pathol. Lab. Med. 113 12 1989 1376 1378
3. A.S. Lawrie, I.J. Mackie, G. Purdy, and S.J. Machin The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers Thromb. Haemost. 81 5 1999 758 762
4. C. Gardiner, I.J. Mackie, R.G. Malia, D.W. Jones, M. Winter, and D. Leeming The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant Br. J. Haematol. 111 4 2000 1230 1235
5. E.M. Jacobsen, L. Barna-Cler, J.M. Taylor, D.A. Triplett, and F. Wisloff The evaluation of clotting times in the laboratory detection of lupus anticoagulants Thromb. Res. 104 4 2001 275 282
6. S.S. Pierangeli, and E.N. Harris Antibodies to cardiolipin and other phospholipids R.A. Asherson R. Cervera J.-C. Piette Y. Shoenfeld The antiphospholipid syndrome 2002 Elsevier 29 43
7. S. Liestol, E.M. Jacobsen, and F. Wisloff Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin Thromb. Res. 105 2 2002 177 182
8. R. Schjetlein, K.E. Sletnes, and F. Wisloff A quantitative, semi-automated and computer-assisted test for lupus anticoagulant Thromb. Res. 69 2 1993 239 250
9. J. Hirsh, T.E. Warkentin, S.G. Shaughnessy, S.S. Anand, J.L. Halperin, and R. Raschke Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 119 1 Suppl. 2001 64S 94S
10. J. Hirsh Heparin N. Engl. J. Med. 324 22 1991 1565 1574
11. B.K. Ip, A.R. Thomson, and H.T. Moriarty A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin Pathology 33 3 2001 347 352
12. L.A. Linkins, J.A. Julian, J. Rischke, J. Hirsh, and J.I. Weitz In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation Thromb. Res. 107 5 2002 241 244
13. R. Al Dieri, R. Wagenvoord, G.W.K. van Dedem, S. Béguin, and H.C. Hemker The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain J. Thromb. Haemost. 1 2003 907 914
14. J.T. Brandt, L.K. Barna, and D.A. Triplett Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH Thromb. Haemost. 74 6 1995 1597 1603
15. T. Exner, D.A. Triplett, D. Taberner, and S.J. Machin Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants Thromb. Haemost. 65 3 1991 320 322
16. M. Greaves, H. Cohen, S.J. Machin, and I. Mackie Guidelines on the investigation and management of the antiphospholipid syndrome Br. J. Haematol. 109 4 2000 704 715
17. S. Beguin, D. Welzel, R. AlDieri, and H.C. Hemker Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy Haemostasis 29 2-3 1999 170 178